🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,762 results for “CTI” Clear

  1. UBT251 Injection 2.0 mg and UBT251 Injection Placebo

    United Therapeutics Europe Ltd

    Type 2 Diabetes Mellitus (T2DM)

    phase 2 small molecule completed

    1 trial

  2. Ubamatamab, TOCILIZUMAB, Ubamatamab, Kevzara 175 mg/ml solution for injection, CEMIPLIMAB, LIBTAYO 350 mg concentrate for solution for infusion., Sarilumab

    Lacuna Pharma Pty Ltd

    Fallopian Tube Cancer, Endometrial Cancer, Ovarian Cancer, Primary Peritoneal Cancer

    phase 2 small molecule active

    1 trial

  3. Udenafil

    Takeda

    Erectile Dysfunction

    phase 2 small molecule terminated

    2 trials

  4. VAXIGRIPTETRA, suspension injectable en seringue préremplie Vaccin grippal quadrivalent (inactivé, à virion fragmenté)

    Tour Hekla

    patients with stable coronary artery disease

    phase 2 small molecule active

    1 trial

  5. VAY736, Placebo Solution for injection or infusion 0 mg/1 mL

    Novartis Pharmaceuticals

    Moderate to severe hidradenitis suppurativa

    phase 2 small molecule active

    1 trial

  6. VDA-1102, VDA-1102 placebo

    Lacuna Pharma Pty Ltd

    Actinic keratosis

    phase 2 small molecule active

    1 trial

  7. VELCADE 3.5 mg powder for solution for injection, DARZALEX 1800 mg solution for injection, DOXORUBICIN HYDROCHLORIDE, DEXAMETHASONE SODIUM PHOSPHATE, DOXORUBICIN HYDROCHLORIDE, CYCLOPHOSPHAMIDE

    Wuhan Createrna Science and Technology Co., Ltd

    Primary plasma cell leukemia

    phase 2 small molecule active

    1 trial

  8. VIR-3434, VIR-2218

    Vir Biotechnology

    Chronic Hepatitis D Virus (HDV) Infection

    phase 2 small molecule active

    1 trial

  9. VIZAMYL 400 MBq/mL solution for injection

    Fondazione Telethon ETS

    cardiac amyloidosis

    phase 2 small molecule active

    1 trial

  10. VLA2001

    United Therapeutics Europe Ltd

    SARS-CoV-2 Virus Infection

    phase 2 mab completed

    1 trial

  11. VOX

    Gilead Sciences Ireland UC

    Hepatitis C Virus Infection

    phase 2 small molecule completed

    1 trial

  12. VP20621

    Takeda

    Clostridium Difficile Infection

    phase 2 mab completed

    1 trial

  13. VRC-HIVDNA016-00-VP

    United Therapeutics Europe Ltd

    HIV Infections

    phase 2 mab completed

    1 trial

  14. VSJ-110

    Vanda Pharmaceuticals Netherlands B.V.

    Allergic Conjunctivitis

    phase 2 small molecule completed

    1 trial

  15. VX-670 Solution for Injection/Infusion

    Vertex Pharmaceuticals (Australia) Pty.

    Myotonic Dystrophy

    phase 2 small molecule active

    1 trial

  16. VX-670 Solution for Injection/Infusion, 0.9% saline solution (w/v)

    Vertex Pharmaceuticals (Australia) Pty.

    Myotonic Dystrophy

    phase 2 small molecule active

    1 trial

  17. Vaborem 1 g/1 g powder for concentrate for solution for infusion

    A.Menarini Australia Pty Limited

    Suspected or confirmed Gram negative infections

    phase 2 small molecule active

    1 trial

  18. Vacuna Dermatophagoides mezcla Placebo, Vacuna Dermatophagoides mezcla 3000 TBU/ml, Test de provocación nasal, Vacuna Dermatophagoides mezcla 6000 TBU/ml, Vacuna Dermatophagoides mezcla 1000 TBU/ml

    Advanced Accelerator Applications

    Allergic rhinitis/rhinoconjunctivitis caused by dust mite allergy

    phase 2 small molecule active

    1 trial

  19. Vectibix 20 mg/ml concentrate for solution for infusion, VALPROIC ACID, VALPROIC ACID, Irinotecan Accord 20 mg/ml concentrato per soluzione perinfusione

    Fondazione Telethon ETS

    RAS/BRAF wild-type metastatic colorectal cancer

    phase 2 small molecule active

    1 trial

  20. Vedolizumab 300 MG Injection [Entyvio]

    Takeda

    Immune Checkpoint Inhibitor-Related Colitis

    phase 2 small molecule active

    1 trial

  21. Vedolizumab intravenous injection

    Takeda

    Ulcerative Colitis

    phase 2 small molecule terminated

    1 trial

  22. Vehicle (Isocyclosporin A 0 mg/mL, 0%), Isocyclosporin A, TROPICAMIDE , SODIUM CHLORIDE , OXYBUPROCAINE

    Dompe' Farmaceutici S.p.A.

    Atopic keratoconjunctivitis (AKC)

    phase 2 small molecule active

    1 trial

  23. Vehicle of TP-03

    Tarsus Pharmaceuticals

    Meibomian Gland Dysfunction

    phase 2 small molecule active

    1 trial

  24. Veklury 100 mg powder for concentrate for solution for infusion

    MEDA Pharma GmbH & Co. KG

    COVID-10 infection

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources